Theory Paper IIDrNB Cardiology – Theory Notes
ASSESSMENT OF REVERSIBILITY OF PAH
ICLINICAL RATIONALE AND PATHOPHYSIOLOGICAL SPECTRUM
- The Core Clinical Question: In patients with Congenital Heart Disease and systemic-to-pulmonary shunts (ASD, VSD, PDA, AVSD) complicated by Pulmonary Arterial Hypertension (PAH-CHD), assessment of reversibility determines whether elevated Pulmonary Vascular Resistance (PVR) is driven by reversible muscular vasoconstriction and medial hypertrophy (Heath-Edwards Grades I to III) or irreversible obliterative intimal fibrosis, plexiform lesions, and necrotizing arteritis (Heath-Edwards Grades IV to VI).
- The Clinical Stakes: Closing a shunt when PVR is still reversible halts pulmonary vascular disease and normalizes life expectancy; conversely, closing a shunt (“eliminating the RV pop-off safety valve”) when PVR is irreversibly fixed precipitates post-operative right ventricular failure, low cardiac output, and worse long-term survival than leaving the patient in Eisenmenger syndrome.
IINON-INVASIVE CLUES OF REVERSIBILITY VS. IRREVERSIBILITY (CLINICAL, ECG, CXR, ECHO)
- Bedside Clinical and Oximetry Clues:
- Favors Reversibility (Left-to-Right Dominant Shunt): Hyperdynamic precordium, displaced LV apex, preserved loud holosystolic (VSD) or continuous (PDA) shunt murmur, apical diastolic flow rumble (indicating Qp:Qs >2:1 across the mitral valve), and resting and post-exercise (6MWT) SpO2 >= 95% (in both upper and lower limbs).
- Favors Irreversibility (Bidirectional / Eisenmenger Shunt): Quiet precordium with parasternal RV heave, palpable P2, disappearance of the VSD/PDA shunt murmur, high-pitched Graham Steell PR murmur, and resting or exercise-induced arterial desaturation (SpO2 <90%) or differential toe cyanosis/clubbing.
- 12-Lead ECG and Chest Radiograph (CXR):
- Favors Reversibility: Biventricular hypertrophy (BVH) or isolated LV volume overload (tall R waves with deep narrow Q waves in V5–V6) on ECG; cardiomegaly with pulmonary plethora extending to the outer third of the lung fields on CXR.
- Favors Irreversibility: Pure Right Ventricular Hypertrophy (RVH) with tall monophasic R in V1 and loss of lateral Q waves on ECG; normal heart size with massive central PA aneurysmal dilatation and peripheral vascular “pruning” (oligemic outer lung fields) on CXR.
- Transthoracic Echocardiography:
- Favors Reversibility: Left Atrial and Left Ventricular enlargement (confirming high pulmonary venous return), pure left-to-right color Doppler flow across the defect, and high-velocity shunt gradient.
- Favors Irreversibility: Normal/small underfilled LA and LV with dilated hypertrophied RV, low-velocity bidirectional or right-to-left shunt flow across the defect, and interventricular septal flattening.
IIIINVASIVE HEMODYNAMIC CRITERIA ON RIGHT HEART CATHETERIZATION (ESC 2020 ACHD VS. PEDIATRIC INDEXED CRITERIA)
- Adult Congenital Heart Disease (ESC 2020 ACHD Guidelines — Absolute PVR in Wood Units):
- PVR less than 3 Wood Units (WU) with a Significant Shunt (Ventricular Volume Overload): Class I (Recommended) for standard percutaneous or surgical shunt closure.
- PVR 3 to less than 5 WU with Qp:Qs > 1.5: Class IIa (Should Be Considered) for closure when significant left-to-right shunting persists without exercise desaturation.
- PVR >= 5 WU: Immediate standard closure is contraindicated (see Treat-and-Repair below for ASD vs. careful expert evaluation in VSD/PDA if Qp:Qs >1.5).
- Eisenmenger Physiology (PVR >= 5 WU with Qp:Qs < 1.5 or Right-to-Left Shunt): Class III (Harm — Strictly Contraindicated).
- Pediatric / Indexed PVR Criteria (AHA / Pediatric PH Consensus — PVRi in Wood Units·m2 and Rp/Rs Ratio):
- PVRi < 4 WU·m2 and Rp/Rs < 0.3: Safe for complete defect closure.
- PVRi 4 to 8 WU·m2 or Rp/Rs 0.3 to 0.5 (“The Grey Zone”): Requires Acute Vasoreactivity Testing (AVT), trial balloon occlusion, or targeted medical pretreatment (often repaired with a fenestrated patch/device).
- PVRi > 8 WU·m2 or Rp/Rs > 0.5 (Unresponsive to AVT): High risk of irreversible PVOD; defect closure is generally contraindicated.
| Assessment Domain | Favors Reversible PAH (Operable Shunt) | Borderline / “Grey Zone” | Favors Irreversible PVOD / Eisenmenger (Inoperable) |
|---|---|---|---|
| Resting & Exercise SpO2 | >=95% at rest and on 6MWT (hands & feet) | Mild drop on peak exercise | <90% at rest or exercise; differential cyanosis/clubbing |
| CXR & ECG | Cardiomegaly + plethora; BVH / LV volume overload (qR in V5–V6) | Moderate cardiomegaly; BVH | Normal CT ratio + peripheral pruning; pure RVH |
| Echocardiography | Dilated LA & LV; pure L-to-R shunt | Predominant L-to-R with brief R-to-L | Small LA/LV; dilated RV; bidirectional / R-to-L shunt |
| ESC 2020 Adult PVR (WU) | PVR < 3 WU (significant shunt) — Class I | PVR 3 to <5 WU (Qp:Qs >1.5) — Class IIa | PVR >= 5 WU with Qp:Qs <1.5 / R-to-L — Class III |
| Pediatric Indexed PVRi (WU·m2) | PVRi < 4 WU·m2 and Rp/Rs < 0.3 | PVRi 4–8 WU·m2 (Perform AVT) | PVRi > 8 WU·m2 and Rp/Rs > 0.5 despite AVT |
IVACUTE VASOREACTIVITY TESTING (AVT) AND TRIAL OCCLUSION IN THE CATH LAB
- Important ESC 2020 Adult vs. Pediatric Nuance: While the 2020 ESC ACHD Guidelines note that acute vasodilator testing in adults has not been prospectively validated to predict late outcome and rely primarily on baseline PVR (<5 WU) and the Treat-and-Repair response, AVT remains widely used in pediatric and Indian tertiary centers for patients in the PVRi 4 to 8 WU·m2 grey zone:
- Agents: Inhaled Nitric Oxide (10 to 40 ppm) + 100% Oxygen (or inhaled Iloprost / IV Epoprostenol). When calculating Fick Qp during 100% O2 inhalation, dissolved plasma O2 (0.003 x PO2) must be included in the Fick denominator.
- Pediatric Operability Criteria on AVT (Barst / Lopes Criteria): A greater than 20 percent decrease in PVRi and Rp/Rs, achieving a final PVRi less than 6 WU·m2 and a final Rp/Rs ratio less than 0.3, accompanied by an increase in Qp:Qs. (Note: These shunt operability criteria are distinct from the Sitbon criteria [mPAP drop >=10 mmHg to <=40 mmHg], which are used only in Idiopathic PAH to select Calcium Channel Blocker therapy.)
- Trial Balloon / Device Occlusion in Large PDA or ASD: Temporary 15-to-20-minute occlusion of a borderline PDA or ASD while recording simultaneous PA and systemic aortic pressures: a >20 to 25 percent drop in PA pressure (or PA/Ao systolic ratio falling <0.5) with preserved systemic aortic pressure and cardiac output supports closure (often using a fenestrated device).
VTHE “TREAT-AND-REPAIR” STRATEGY AND THE INDIAN CONTEXT
- “Treat-and-Repair” Protocol: In patients presenting with baseline PVR >= 5 WU (or PVRi 6 to 8 WU·m2) who still exhibit a net left-to-right shunt, initiating 6 to 12 months of targeted PAH pharmacotherapy (Endothelin Receptor Antagonist [Bosentan/Macitentan] + PDE-5 Inhibitor [Sildenafil/Tadalafil]) followed by a repeat RHC allows fenestrated defect closure (creating a 4 to 6 mm unidirectional or calibrated pop-off) if PVR falls to less than 5 WU with Qp:Qs greater than 1.5, with lifelong continuation of PAH drugs post-closure.
- Practical Considerations in the Indian Context:
- Hydration and Altitude: Ensure patients are normovolemic and free of acute lower respiratory infection or severe anemia prior to RHC, as dehydration and hypoxia falsely elevate PVR.
- Abandonment of Open Lung Biopsy: Open lung biopsy for Heath-Edwards histological grading is obsolete and not recommended due to high perioperative mortality in PAH and non-uniform patchy distribution of plexiform lesions.
Key references
- Baumgartner H, De Backer J, Babu-Narayan SV, et al.: 2020 ESC Guidelines for the management of adult congenital heart disease, European Heart Journal, 2020.
- Humbert M, Kovacs G, Hoeper MM, et al.: 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension, European Heart Journal, 2022.
- Lopes AA, O’Leary PW: Measurement, interpretation and use of haemodynamic parameters in pulmonary hypertension associated with congenital cardiac disease, Cardiology in the Young, 2009.
meritmedscript.comDr. Sidhartha Mullapudi
